Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Industry's Cure For Biomarker Development Woes: Standards, Transparency, Incentives

Executive Summary

Panelists at BIO also said FDA should leverage external expertise in designing biomarker development programs and adopt an advisory committee approach to reviewing qualification packages.

Advertisement

Related Content

Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register